 Cystadenocarcinoma, Serous
"Cystadenocarcinoma, Serous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
| Descriptor ID |
D018284
|
| MeSH Number(s) |
C04.557.470.200.025.480.240 C04.557.470.590.480.240
|
| Concept/Terms |
Cystadenocarcinoma, Serous- Cystadenocarcinoma, Serous
- Cystadenocarcinomas, Serous
- Serous Cystadenocarcinoma
- Serous Cystadenocarcinomas
|
Below are MeSH descriptors whose meaning is more general than "Cystadenocarcinoma, Serous".
Below are MeSH descriptors whose meaning is more specific than "Cystadenocarcinoma, Serous".
This graph shows the total number of publications written about "Cystadenocarcinoma, Serous" by people in this website by year, and whether "Cystadenocarcinoma, Serous" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 3 | 3 | | 2002 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 1 | 2 | | 2012 | 1 | 0 | 1 | | 2015 | 3 | 1 | 4 | | 2016 | 2 | 0 | 2 | | 2017 | 1 | 1 | 2 | | 2018 | 1 | 2 | 3 | | 2019 | 1 | 1 | 2 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystadenocarcinoma, Serous" by people in Profiles.
-
Nath A, Cosgrove PA, Mirsafian H, Christie EL, Pflieger L, Copeland B, Majumdar S, Cristea MC, Han ES, Lee SJ, Wang EW, Fereday S, Traficante N, Salgia R, Werner T, Cohen AL, Moos P, Chang JT, Bowtell DDL, Bild AH. Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nat Commun. 2021 05 24; 12(1):3039.
-
Tatebe K, Hasan Y, Son CH. Adjuvant vaginal brachytherapy and chemotherapy versus pelvic radiotherapy in early-stage endometrial cancer: Outcomes by risk factors. Gynecol Oncol. 2019 12; 155(3):429-435.
-
Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 12 19; 381(25):2403-2415.
-
Javellana M, Hoppenot C, Lengyel E. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. Gynecol Oncol. 2019 02; 152(2):228-234.
-
Mills KA, Roach ST, Quinn JM, Guo L, Beck HM, Lomonosova E, Ilivicky AR, Starks CM, Lawrence JA, Hagemann AR, McCourt C, Thaker PH, Powell MA, Mutch DG, Fuh KC. SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth. Gynecol Oncol. 2018 11; 151(2):337-344.
-
Chapel DB, Joseph NM, Krausz T, Lastra RR. An Ovarian Adenocarcinoma With Combined Low-grade Serous and Mesonephric Morphologies Suggests a Müllerian Origin for Some Mesonephric Carcinomas. Int J Gynecol Pathol. 2018 Sep; 37(5):448-459.
-
Hoppenot C, Eckert MA, Tienda SM, Lengyel E. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 2018 01; 148(1):204-212.
-
Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017 11; 147(2):243-249.
-
Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 12; 6(12):1342-1351.
-
Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):13587-98.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|